Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen‐4 (CTLA‐4), programmed cell death ligand‐1 (PD‐L1) and programmed cell death‐1 (PD‐1). Immunotherapy targeting the PD‐1/PD‐L1 checkpoints has shown promising efficacy in non‐small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the simultaneous inhibition of other checkpoints could improve outcomes. Lymphocyte‐activation gene‐3 (LAG‐3) is another vital checkpoint that may have a synergistic interaction with PD‐1/PD‐L1. Here we review the LAG‐3 function in cancer, clinical trials with agents targeting LAG‐3 and the correlation of LAG‐3 with other checkpoints.

[1]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[2]  Yehong Liu,et al.  Lymphocyte activation gene 3 negatively regulates the function of intrahepatic hepatitis C virus‐specific CD8+ T cells , 2015, Journal of gastroenterology and hepatology.

[3]  L. Diaz,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[4]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[7]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[9]  C. Qiu,et al.  The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects , 2015, The Journal of Immunology.

[10]  H. Saito,et al.  Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery , 2015, Yonago acta medica.

[11]  M. Kimani,et al.  Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment , 2015, Retrovirology.

[12]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[13]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[14]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[15]  B. Vergani,et al.  Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. , 2014, The Journal of investigative dermatology.

[16]  N. Jones,et al.  Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load. , 2014, AIDS research and human retroviruses.

[17]  R. Luong,et al.  Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation , 2014, PloS one.

[18]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[19]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[20]  L. Yao,et al.  Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. , 2013, Immunology letters.

[21]  Kumar Kuna,et al.  Research Highlights and Editors’ Picks , 2013 .

[22]  Yong-hoon Chung,et al.  Construction, and in vitro and in vivo analyses of tetravalent immunoadhesins. , 2012, Journal of microbiology and biotechnology.

[23]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[24]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[25]  P. Klenerman.  Faculty Opinions recommendation of Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. , 2012 .

[26]  C. Drake,et al.  Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 , 2011, The Journal of Immunology.

[27]  S. Beyaz,et al.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. , 2011, Blood.

[28]  F. Aoudjit,et al.  MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis , 2011, The Journal of Immunology.

[29]  T. Okazaki,et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.

[30]  N. Rothman,et al.  Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut , 2010, American journal of hematology.

[31]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Parmiani,et al.  LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites , 2010, The Journal of Immunology.

[33]  Š. Pospíšilová,et al.  High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. , 2010, The Journal of molecular diagnostics : JMD.

[34]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[35]  Sang Yeol Lee,et al.  Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223). , 2010, Veterinary immunology and immunopathology.

[36]  D. Getnet,et al.  Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1 , 2009, The Journal of Immunology.

[37]  C. Drake,et al.  LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1 , 2009, The Journal of Immunology.

[38]  S. Chanock,et al.  Abstract A78: Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut , 2008 .

[39]  D. Getnet,et al.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. , 2007, The Journal of clinical investigation.

[40]  Bing Li,et al.  CD4+CD25+Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[41]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[42]  R. Khanna,et al.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. , 2006, Blood.

[43]  F. Triebel,et al.  A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321. , 2006, Vaccine.

[44]  G. Parmiani,et al.  Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. , 2006, Cancer research.

[45]  Malgorzata Kisielow,et al.  Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells , 2005, European journal of immunology.

[46]  P. Musiani,et al.  Immunological mechanisms elicited at the tumour site by lymphocyte activation gene‐3 (LAG‐3) versus IL‐12: sharing a common Th1 anti‐tumour immune pathway , 2005, The Journal of pathology.

[47]  In-Jeong Kim,et al.  Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1 , 2004, The Journal of Immunology.

[48]  F. Triebel.  LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. , 2003, Trends in immunology.

[49]  S. Buisson,et al.  MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). , 2003, Blood.

[50]  P. Musiani,et al.  LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.

[51]  D. Vignali,et al.  The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells , 2003, European journal of immunology.

[52]  S. Buisson,et al.  MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells. , 2003, Vaccine.

[53]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[54]  M. D’Elios,et al.  Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo , 2002, European journal of immunology.

[55]  N. Burdin,et al.  Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1 , 2002, The Journal of Immunology.

[56]  P. Gaulard,et al.  T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. , 2001, European journal of cancer.

[57]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[58]  F. Triebel,et al.  A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens1 , 2000, The Journal of Immunology.

[59]  M. Dréano,et al.  Lymphocyte activation gene‐3 induces tumor regression and antitumor immune responses , 1999, European journal of immunology.

[60]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[61]  S. Hannier,et al.  The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. , 1999, International immunology.

[62]  M. Avice,et al.  Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. , 1999, Journal of immunology.

[63]  G. Bismuth,et al.  CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. , 1998, Journal of immunology.

[64]  T. Satoh,et al.  CD4 dimerization and oligomerization: implications for T-cell function and structure-based drug design. , 1998, Immunology today.

[65]  F. Annunziato,et al.  Expression and release of LAG‐3‐encoded protein by human CD4+ T cells are associated with IFN‐γ production , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  F. Pagès,et al.  T cell major histocompatibility complex class II molecules down‐regulate CD4+ T cell clone responses following LAG‐3 binding , 1996, European journal of immunology.

[67]  D. Bruniquel,et al.  CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins , 1995, European journal of immunology.

[68]  A. Smolyar,et al.  Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[69]  C. Auffray,et al.  Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens , 1992, The Journal of experimental medicine.

[70]  S. Roman-Roman,et al.  LAG-3, a novel lymphocyte activation gene closely related to CD4 , 1990, The Journal of experimental medicine.

[71]  C. Liu,et al.  Microenvironment and Immunology Immune InhibitoryMolecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2012 .

[72]  A. Oxenius,et al.  On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. , 2010, International immunology.

[73]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[74]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[75]  D. Bruniquel,et al.  Genomic organization of the human LAG-3/CD4 locus , 1997, Immunogenetics.

[76]  T. Iijima,et al.  Expression of MHC class II antigens in human lung cancer cells , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.

[77]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[78]  M. Selman,et al.  IMMUNOPATHOLOGY AND INFECTIOUS DISEASES LAG 3 Expression in Active Mycobacterium tuberculosis Infections , 2022 .

[79]  A. Smolyar.  Oligomerization of CD 4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gpl 20 , 2022 .